Traditional treatment modalities for patients with advanced lung disease are chemotherapy, radiation therapy, bevacizumab (Avastin, a targeted agent against vascular endothelial growth factor [VEGF]), or a combination of these options; however, despite multimodal treatment, high rates of local and distant failure are common, and adverse events can be serious (Ramnath et al., 2013; Huber, Reck, & Thomas, 2013; Pilkington et al., 2015; Sun, Ma, Zhang, Zou, & Han, 2015). This evidence concerns the gene VEGFA and lung disorder.